Dalpiciclib (SHR6390) is a highly selective CDK4/6 inhibitor, which has been proven effective in the DAWNA‐1 [19] and DAWNA‐2 [20] trials, and approved for the treatment of HR-positive, HER2-negative ABC in China. The gene discussed is ERBB2; the disease is aneurysmal bone cyst.